KOSDAQBiotech & Pharma352770

Celestra

₩5,250 0.00%2026-11-18 close
Market Cap
₩13.6B
Turnover
₩0
Volume
0 shares
Shares out.
2.6M
PER
—
PBR
—
EPS
-₩1,653
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Sharp Revenue Decline and Listing Status Define the Case

Celestra narrowed its operating loss in 2025, but revenue has fallen for three consecutive years to KRW 2.01 billion, and the termination of its rehabilitation procedure and a suspended delisting process in 2026 have made business continuity the central question.

  1. 1

    Revenue for 2025 was KRW 2.01 billion, down 76.4% year on year, making it the smallest year in the 2022–2025 span.

  2. 2

    Operating loss shrank from KRW 28.7 billion in 2024 to KRW 7.76 billion in 2025, yet the operating margin was still -386.5% in 2025.

  3. 3

    Third-quarter 2026 operating loss was KRW 854 million, narrower than a year earlier, while quarterly revenue was reported below KRW 300 million.

  4. 4

    After a delisting decision in June 2026, an injunction application suspended the process, and a qualification review was added following the November 16, 2026 filing.

  5. 5

    The audit opinion on fiscal 2025 was a disclaimer of opinion, and the company filed an objection to the delisting ground.

02

Business structure

Celestra is a genome-based diagnostics company founded in July 2011 and listed on KOSDAQ in December 2020. The company has built its business around four areas: genome-based healthcare, a liquid biopsy platform, cancer diagnosis and monitoring, and early cancer detection.

Its technology detects circulating tumor cells (CTC) and cell-free DNA (cfDNA) from blood at the same time, supported by multi-omics analysis capabilities. An in-house bio big-data center accumulates large datasets for research and commercialization.

Revenue is listed as roughly 94 percent services and 6 percent medical devices by Alphasquare, a figure whose collection date is not stated. In 2023 the company carried out national R&D projects on infectious disease and epidemiological modeling.

Its former name was Clinomics, and it set up subsidiaries in the United States and United Kingdom to pursue overseas expansion. Press reports linked its rehabilitation filing to a slowdown in growth of its main business segment and a heavy fixed-cost burden.

A 2026 sale report cited the book value of its production site in Ulju County and its research center in Osong, Chungbuk at roughly KRW 9.5 billion.

The diagnostics market is contested on technology and price, while large listed peers in the biopharma sector such as Samsung Biologics and Celltrion center on contract manufacturing and biosimilars, a different structure from Celestra's service-based diagnostics model.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩1.1B-₩1.9B−174.4%
2025Q4—-₩200M—
2026Q1₩24,087,300-₩300M−1052.6%
2026Q2₩0-₩400M—
2026Q3₩0-₩900M—
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩23.1B-₩10.8B-₩10.2B−46.7%−19.3%82.5%
2023₩11.4B-₩34.6B-₩42.4B−303.2%−109.8%91.0%
2024₩8.5B-₩28.7B-₩46.9B−337.7%−861.0%877.7%
2025₩2B-₩7.8B-₩11.8B−386.5%—−395.7%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-18

04

Earnings analysis

Annual results show revenue shrinking while losses persisted. Revenue fell from KRW 23.1 billion in 2022 to KRW 11.4 billion in 2023 (down 50.6% year on year), to KRW 8.5 billion in 2024 (down 25.5%), and to KRW 2.01 billion in 2025 (down 76.4%).

Revenue declined for three consecutive years from 2023 through 2025, with 2022 the largest year and 2025 the smallest in the 2022–2025 span. Operating loss widened from KRW 10.8 billion in 2022 to KRW 34.6 billion in 2023, then narrowed to KRW 28.7 billion in 2024 and KRW 7.76 billion in 2025.

The operating margin moved from -46.7% in 2022 to -303.2% in 2023, -337.7% in 2024 and -386.5% in 2025, which suggests revenue fell faster than costs could be cut.

Net loss attributable to controlling shareholders was KRW 10.2 billion in 2022, KRW 42.4 billion in 2023, KRW 46.9 billion in 2024 and KRW 11.8 billion in 2025. Total net loss including non-controlling interests was KRW 47.1 billion in 2024.

The debt ratio, total liabilities divided by total equity, rose from 82.5% in 2022 and 91.0% in 2023 to 877.7% in 2024. Operating cash outflows were KRW 12 billion in 2022, KRW 10.7 billion in 2023, KRW 11.3 billion in 2024 and KRW 5.59 billion in 2025.

Press coverage tied the 2023 and 2024 expansion of losses to aggressive investments, including a hotel acquisition for about KRW 18.5 billion, a 40 percent stake in a mushroom-cultivation company and convertible bond issuance.

Quarterly operating loss went from KRW 1.87 billion in the third quarter of 2025 to KRW 168 million in the fourth quarter, then widened to KRW 254 million, KRW 447 million and KRW 854 million across the first three quarters of 2026, making five consecutive loss-making quarters.

Revenue moved from KRW 1.07 billion in the third quarter of 2025 to KRW 24.09 million in the first quarter of 2026, and third-quarter 2026 revenue was reported below KRW 300 million. Net loss attributable to controlling shareholders over the last four quarters totaled KRW 4.22 billion.

05

Industry analysis

Celestra operates in the genome-based diagnostics market, where demand centers on early cancer detection and liquid biopsy and depends on the spread of precision medicine and testing demand. The company's results, however, show weakening ability to convert that demand into revenue.

An August 2026 press report pointed to a rising number of biotech and healthcare companies facing disclaimers of opinion and delisting grounds. Blotter identified a prolonged industry slump and liquidity pressure as the background to the rehabilitation filing.

Larger listed peers in the sector such as Samsung Biologics and Celltrion are built around contract manufacturing and biosimilars, a revenue structure different from Celestra's service-based diagnostics model. Celestra's KRW 2.01 billion of revenue in 2025 is very small against listed peers in the same industry.

Its market capitalization ranks near the bottom of the life sciences and engineering industry group. The most direct cycle signal at present is that the company's results do not show a recovery in the industry.

Its liquid biopsy platform and big-data center are cited as differentiators, but the speed at which they translate into revenue remains the key question.

06

Outlook

The business plan the company has made public centers on securing funding and maintaining its listing. A sale report in the first half of 2026 said Samil PricewaterhouseCoopers was appointed as sale adviser and that a pre-approval merger and acquisition process inside the rehabilitation framework had begun.

A delisting decision was made on June 8, 2026, and the company filed an injunction application on June 9, leaving the delisting steps, including the final trading period, on hold. The Korea Exchange said it would proceed with follow-up steps once the related litigation is decided.

In August 2026 the Suwon Bankruptcy Court terminated the rehabilitation procedure after no rehabilitation plan was submitted, and the company said it would consider refiling once a new investor is confirmed.

A third-quarter 2026 report filed on November 16, 2026 showed recent-quarter revenue below KRW 300 million, which added a qualification review ground.

For the fiscal 2025 audit opinion, the company filed an objection on April 28, 2026, and the exchange said it would deliberate the matter together with the fiscal 2024 opinion ground.

The next checkpoints are the outcome of the injunction litigation, whether a new investor is confirmed, and the revenue and audit opinion in the 2026 annual report.

07

Valuation

PER
—
PBR
—
ROE
—
EPS
-₩1,653
BPS
—
Dividend per share
₩0

Celestra's price-to-earnings ratio is not calculated because the company recorded net losses in each of the last four quarters. Where there are no earnings, earnings-based multiples carry little meaning, so the comparison shifts toward asset value and business continuity.

The company pays no dividend, so its dividend yield sits well below the industry average. Market capitalization is well above year-end 2025 total equity, meaning the premium to net asset value is large.

Total equity at year-end 2025 was KRW 6.22 billion, all attributable to controlling shareholders, against total liabilities of KRW 24.6 billion. The five-year average PER reflects profitable years and is hard to apply directly to the current loss-making period.

Its market capitalization ranks near the bottom of the life sciences and engineering industry group. For this stock, the listing procedure and funding events weigh more heavily on interpretation of value than the reported earnings metrics do.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-18

08

Bull factors

Cost cuts narrowed losses

A year-to-date analysis through the third quarter of 2025 credited improved cost ratios and cost cuts with a sharp reduction in operating loss. Full-year 2025 operating loss was KRW 7.76 billion against KRW 28.7 billion in 2024, and the third-quarter 2026 loss was narrower than a year earlier. The narrowing direction is cited as a supporting factor for the bull case.

Debt clean-up hoped for with a new investor

A first-half 2026 report noted that a new investor entering the sale process could clear existing and contingent debts and remove impaired assets. The company has said it would consider refiling for rehabilitation once an investor is confirmed. Whether this path is realized has not yet been determined.

Liquid biopsy technology and data assets

Celestra holds technology that detects circulating tumor cells and cell-free DNA from blood at the same time, along with multi-omics analysis. Its in-house bio big-data center accumulates large datasets usable for research and commercialization. A company information site lists 18 patents in total.

09

Bear factors

Weakening revenue base

Revenue fell from KRW 11.4 billion in 2023 and KRW 8.5 billion in 2024 to KRW 2.01 billion in 2025, a third straight annual decline. First-quarter 2026 revenue was KRW 24.09 million. Third-quarter 2026 revenue was reported below KRW 300 million, which triggered an added qualification review.

Audit opinion and listing procedures

The fiscal 2025 audit opinion was a disclaimer of opinion, and the company filed an objection on April 28, 2026. A delisting decision was made on June 8, 2026, and the procedure is on hold pending an injunction. The rehabilitation procedure was terminated in August 2026.

Limited funding routes and reports of a complaint against management

Total equity at the end of 2025 was KRW 6.22 billion against total liabilities of KRW 24.6 billion. With no new investor confirmed, funding routes remain limited.

Press reports said a complaint had been filed against the CEO over alleged breach of trust and violations of capital markets law, and that signs of fund outflows before the delisting were reported.

10

Risk factors

Listing status

A delisting decision is in place, and the process remains suspended until the court rules on the injunction. If the ruling goes against the company, trading conditions could change quickly. The added qualification review also leaves the exchange room to take further steps.

Liquidity and funding

Reports said the company had lost its ability to raise funds on its own, and that lenders declined to extend loan maturities. Operating losses have widened each quarter since the first quarter of 2026, which accelerates cash consumption. Without new capital, the timing of any rehabilitation refiling remains unclear.

Accounting and governance

The fiscal 2024 audit opinion was qualified, and the fiscal 2025 opinion was a disclaimer. The audit report was also delayed beyond the statutory deadline in 2026. Reports of a complaint against management and possible fund outflows add uncertainty about the reliability of financial disclosures.

11

What to watch next

  1. Date TBD (after the injunction ruling)

    Whether the delisting procedure resumes and the outcome of the qualification review. The court ruling is the turning point for trading conditions.

  2. Date TBD (upon confirmation of a new investor)

    Whether a rehabilitation refiling takes place, the acquisition terms, and how existing and contingent debts are handled. This determines whether a funding route opens.

  3. March 31, 2027 (statutory deadline for the 2026 annual report)

    Full-year 2026 revenue and operating loss, and the fiscal 2026 audit opinion. Whether the opinion moves away from the fiscal 2025 disclaimer is the checkpoint.

12

Overall view

Celestra's revenue fell from KRW 23.1 billion in 2022 to KRW 2.01 billion in 2025, and its operating loss narrowed from KRW 28.7 billion in 2024 to KRW 7.76 billion in 2025.

Operating losses have widened each quarter since the first quarter of 2026, reaching KRW 854 million in the third quarter, and that quarter's revenue was reported below KRW 300 million.

The rehabilitation procedure was terminated in August 2026, and the delisting process is on hold pending the outcome of the injunction litigation. With total equity of KRW 6.22 billion and total liabilities of KRW 24.6 billion at year-end 2025, financial capacity is limited.

Supporters point to lower losses from cost cuts, the liquid biopsy technology and data assets, and the possibility of debt clean-up with a new investor. Critics point to the weakening revenue base, the disclaimer of opinion and listing procedures, and difficulty in raising funds.

The judgment on business continuity now rests largely on a single question, whether the company stays listed. The next checkpoints are the outcome of the injunction litigation, confirmation of a new investor, and the revenue and audit opinion in the 2026 annual report.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. comp.fnguide.com
  2. butler.works
  3. thevc.kr
  4. valueline.co.kr
  5. topstarnews.net
  6. topstarnews.net
  7. m.sedaily.com
  8. alphasquare.co.kr
  9. topstarnews.net
  10. news.nate.com
  11. m.news.nate.com
  12. bloter.net
  13. news.nate.com
  14. ebn.co.kr
  15. m.news.nate.com
  16. m.news.nate.com
  17. m.news.nate.com
  18. tokenpost.kr

Report written 2026-11-19 · Data as of 2026-11-18

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis